Clinical Trials
A List of Clinical Trials and Research Studies on EGIDs
Included on this page
Is clinical trial information and other test information. Please click on the link to learn more details about the trial, its purpose, who may participate, locations, and phone numbers for more information. Please seek advice from your medical teams about the clinical trials or studies you are intrested in. The items are listed in date order & updated periodically:
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
To check eligibility answer these few questions.
To learn more visit, Bristol Myers Squibb
Trial Overview
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be randomized at the beginning of the study into 3 treatment arms: - Placebo for Induction and Maintenance - CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once every other week for Maintenance - CC-93538 360 mg SC once weekly for Induction and Maintenance
DESTINY study for adults with HES
To check eligibility take this survey
To learn more visit, https://gskdestinystudy.com/?utm_source=cured
GlaxoSmithKline
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy.
Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.
OCEAN study for adults with EGPA
To learn more visit, https://gskoceanclinicaltrial.com/?utm_source=cured
GlaxoSmithKline
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Study in Pediatrics with HypEREosinophilic syndrome (SPHERE)
To learn more visit, www.sphereclinicaltrial.com
GlaxoSmithKline
The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard-of-care (SoC) therapy.
A Study of Lirentelimab (AK002) in Patients with Active Eosinophilic Duodenitis (EoDyssey)
Allakos EoD Only Patient Brochure
Contact: To learn more, call 1-833-209-8331 or visit www.clinicaltrials.gov (NCT# 04856891)
We want to inform you about an experimental drug, lirentelimab, that is being studied for patients with various inflammatory and allergic diseases, including eosinophilic gastrointestinal diseases such as EOSINOPHILIC DUODENITIS (EoD). Studies are currently ongoing across the United States in these diseases.
If you have been diagnosed with eosinophilic duodenitis (EoD) or eosinophilic gastroenteritis (EGE), or have chronic, unresolved GI symptoms and suspect you may have EoD, you may be eligible to participate in a clinical study.
Atopic dermatitis, Bullous pemphigoid and chronic spontaneous urticaria-Benra Derm Trials Atopic dermatitis, Bullous pemphigoid and chronic spontaneous urticaria are all now on our Benra Derm Trials
How to participate: Qualification Questionnaire
IQVIA
Study Start Date: November 2020
Contact: Fill out Questionnaire for Qualification and IQVIA will contact you.
A Study of Benralizumab in Patients with Eosinophilic Esophagitis (MESSINA)
How to participate: NCT04543409
Study website: MESSINA
AstraZeneca
Study Start Date: September 2020
Contact: Clinic Location based on Location
Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. (MANDARA)
How to participate: NCT04157348
AstraZeneca
Study Start Date: November 2019
Contact: Clinic Location based on Location
A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES) (NATRON)
How to participate: NCT04191304
Study Website: NATRON
AstraZeneca
Study Start Date: December 2019
Contact: Clinic Location based on Location
How to participate: NCT03633617
Regeneron Pharmaceuticals
Study Start Date:August 2018
Contact: Clinical Trials Administrator (844) 734-6643 clinicaltrials@regeneron.com
For children, teens, and adults 12 to 60 years old.
How to participate: Benralizumab Eosinphilic Gastritis Study brochure_Final
Cininnati Children’s Hospital Medical Center
Contact: Marc Rothenberg, MD, PhD (513) 803-0257
Cristin Murray-Petzold (513) 803-9079
Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE)
Study Start Date: January 2020
Ellodi Pharmaceuticals, LP
How to Participate: NCT04281108
VOYAGE
Patient Outreach Center
Arena Pharmaceuticals
How to Participate: Arena Pharmaceuticals
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
Study Start Date: June 2015
National Institute of Allergy and Infectious Diseases (NIAID)
How to Participate: NTC02523118
Food Antigen in Eosinophilic Esophagitis (EoE)
Study Start Date: May 2015
Mayo Clinic
How to Participate: NCT02434705
Budesonide Effervescent Tablet vs. Placebo in Active Eosinophilic Esophagitis (EOS-1)
Study Start Date: April 2015
Dr. Falk Pharma GmbH
How to Participate: NCT02434029
Fibrostenotic Eosinophilic Esophagitis: Assessment Tools
Study Start Date: May 2015
University of Colorado, Denver
How to Participate: NCT02453126
Esophageal String Test in Eosinophilic Esophagitis
Study Start Date: December 2013
University of Colorado, Denver
How to Participate: NTC02008903
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
Study Start Date: December 2005
Children’s Hospital Medical Center, Cincinnati
How to Participate: NTC00267501